首页|Colorectal cancer cells expressing Mex3a drive recurrence after chemotherapy
Colorectal cancer cells expressing Mex3a drive recurrence after chemotherapy
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Many patients with colorectal cancer (CRC) relapse after chemotherapy. Tumor cells that do not completely adapt to their environment (owing to an incomplete set of CRC driver mutations) enter a latent state, in which the expression of Mex3a is upregulated. Mex3a+ cells are chemoresistant and reactivate after treatment, which leads to regeneration of the disease. The problem:Chemotherapy is part of the standard of care for patients with advanced CRC. However, tumor cells that are capable of resisting chemotherapy (drug-tolerant persister cells (DTPs)) limit the benefit of this treatment. The identity and features of the DTP population remain controversial, in part because experimental model systems do not reproduce well the heterogeneous tumor cell phenotypes and behaviors that are dictated by the distinct mutations and environmental signals that characterize CRC. Moreover, the gene expression programs that are co-opted by DTPs before treatment, during chemotherapy and in the recurrence phase are poorly understood. Identifying marker genes for DTPs and implementing genetic lineage-tracing systems that enable tracking of this population and its progeny is crucial to tackle this knowledge gap. Progress in this area may improve the effects of chemotherapy in patients with CRC and aid in the prevention of disease recurrence.
NSTL
